latest news releases from the newsroom
Gate Gourmet Announces New CFO
ZURICH, Switzerland, May 6, 2003 (PRIMEZONE) -- Gate Gourmet is pleased to announce that Guy Dubois will join Gate Gourmet International as Chief Financial Officer and Executive Vice President on July 1, 2003. After he graduated from business school, Guy Dubois relocated to Sweden and worked for IBM. In 1998, he joined the European Organization for Nuclear Research (CERN) in Geneva, Switzerland. Since 1994 Guy Dubois was employed by Hoffmann-LaRoche, where he worked in various international positions in the field of finance. He started in Corporate Finance in Switzerland and then joined Roche Vitamins Asia Pacific Pte Ltd., Singapore as Area Manager Finance & Administration.
Telenor: Reduced SMS prices as of today
OSLO, Norway, May 6, 2003 (PRIMEZONE) -- Telenor Mobil (Nasdaq:TELN) (Other OTC:TELNF) has recently announced extensive price cuts in June. The SMS prices are however effective already today. Thus, the price of an SMS will start at only NOK 0.69 for Telenor Mobil customers."Prices in general will be adjusted in June, but we would like to give our customers the benefit of lower SMS prices already today," said assistant Head of Information Esben Tuman Johnsen in Telenor Mobil.
Astex and Schering AG Announce Multi-Target Drug Discovery Alliance with Focus on Cancer Drugs
CAMBRIDGE, United Kingdom, May 6, 2003 (PRIMEZONE) -- Astex Technology, the fragment-based drug discovery company and Schering AG (FSE:SCH) NYSE:SHR), today announced a major multi-target drug discovery alliance. The four year agreement relates to the discovery of novel drugs for various therapeutic indications especially focusing on orally available small molecule drugs targeting solid tumors. Schering will fund Astex's research programs relating to the collaboration, providing discovery and clinical milestone payments plus royalties based on the sales of each product which reaches market approval. Schering will be responsible for clinical development and has an option to retain worldwide exclusive marketing rights for all identified compounds. Under the terms of the agreement, multiple targets will be selected each year with an option to extend the collaboration for a further four-year term to include additional targets
Innogenetics Announces Positive Results in Pivotal Preclinical Study in Sepsis
GENT, Belgium, May 6, 2003 (PRIMEZONE) -- Innogenetics (Other OTC:INGTF) today reported the results of its pivotal preclinical evaluation of a proprietary anti-inflammatory monoclonal antibody, INNO 202, for the treatment of severe sepsis. The very positive results achieved in a clinically relevant animal model open the prospects for clinical trials in humans in the near future.